Showing results (11-20 of 451) with videos related to
Sort By:
Pageof 46
Inflammatory Bowel Diseases|March 15, 2006
Evaluation of short-term responsiveness and cutoff values of inflammatory bowel disease questionnaire in Crohn's diseaseTibor Hlavaty, Philippe Persoons, Severine Vermeire, et al.Scandinavian Journal of Gastroenterology|May 21, 2019
Short Health Scale: a valid and reliable measure of quality of life in Dutch speaking patients with inflammatory bowel diseaseSofie Coenen, Ellen Weyts, Patricia Geens, et al.Gut|April 29, 2017
Clinical relevance of detecting anti-infliximab antibodies with a drug-tolerant assay: post hoc analysis of the TAXIT trialThomas Van Stappen, Niels Vande Casteele, Gert Van Assche, et al.British Journal of Clinical Pharmacology|January 12, 2019
Optimising infliximab induction dosing for patients with ulcerative colitisErwin Dreesen, Ruben Faelens, Gert Van Assche, et al.Expert Opinion on Emerging Drugs|March 16, 2007
Emerging drugs to treat Crohn's diseaseGert van AsscheThe American Journal of Gastroenterology|December 5, 2013
Intravenous iron for the treatment of iron deficiency in IBD: the pendulum is swingingGert Van AsscheJournal of Crohn'S & Colitis|September 22, 2018
Higher Infliximab Trough Levels Are Associated With Better Outcome in Paediatric Patients With Inflammatory Bowel DiseaseKaren van Hoeve, Erwin Dreesen, Ilse Hoffman, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 24, 2006
Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitisDavid N Moskovitz, Gert Van Assche, Benedikte Maenhout, et al.European Journal of Gastroenterology & Hepatology|October 30, 2015
Thromboembolism as an important complication of inflammatory bowel diseaseLize Bollen, Niels Vande Casteele, Vera Ballet, et al.Therapeutic Drug Monitoring|January 12, 2019
Efficacy, Pharmacokinetics, and Immunogenicity is Not Affected by Switching From Infliximab Originator to a Biosimilar in Pediatric Patients With Inflammatory Bowel DiseaseKaren van Hoeve, Erwin Dreesen, Ilse Hoffman, et al.Pageof 46